Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine Pathology
Published in: Endocrine Pathology 2/2019

01-06-2019 | Hyperparathyroidism

Diagnostic Pitfall: Parathyroid Carcinoma Expands the Spectrum of Calcitonin and Calcitonin Gene-Related Peptide Expressing Neuroendocrine Neoplasms

Authors: Anjelica Hodgson, Sara Pakbaz, Farnoosh Tayyari, James Edward Massey Young, Ozgur Mete

Published in: Endocrine Pathology | Issue 2/2019

Login to get access

Excerpt

A 59-year-old man with primary hyperparathyroidism (PTH 76 pmol/L, normal range 2–9 pmol/L) and associated hypercalcemia (3.4 mmol/L, normal range 2.15–2.55 mmol/L) was found to have a CT and Sestamibi scan-localized left thyroid component neck mass. Intraoperatively, the mass was noted to be adherent to the left side of the thyroid and required en bloc resection of the mass with the left lobe. In addition, the patient underwent right hemithyroidectomy for nodular goiter. Postoperatively, the serum PTH level was noted to have significantly dropped (5.6 pmol/L, within normal range), supporting the uniglandular source of hyperparathyroidism. …
Literature
1.
DeLellis RA, Arnold A, Bilezikian JP, Eng C, Larsson C, Lloyd RV, Mete O. Parathyroid carcinoma. In: Lloyd RV, Osamura RY, Klöppel G, Rosai J. eds. WHO Classification of Tumours of Endocrine Organs. 4th ed. Vol. 10. Lyon, France: WHO Press; 2017, pp: 147–152.
2.
Erickson LA, Mete O. Immunohistochemistry in Diagnostic Parathyroid Pathology. Endocr Pathol. 2018; 29:113–129.CrossRefPubMed
3.
Kaltsas G, Androulakis II, de Herder WW, Grossman AB. Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer. 2010;17: R173–R193.CrossRefPubMed
4.
Bauer JL, Toluie S, Thompson LDR. Metastases to the Parathyroid Glands: A Comprehensive Literature Review of 127 Reported Cases. Head Neck Pathol. 2018; 12:534–541.CrossRefPubMed
5.
Nozières C, Chardon L, Goichot B, Borson-Chazot F, Hervieu V, Chikh K, Lombard-Bohas C, Walter T. Neuroendocrine tumors producing calcitonin: characteristics, prognosis and potential interest of calcitonin monitoring during follow-up. Eur J Endocrinol. 2016; 174:335–334CrossRefPubMed
6.
Duan K, Mete O. Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers. Cancer Cytopathol. 2016; 124:871–884.CrossRefPubMed
7.
Khan A, Tischler AS, Patwardhan NA, DeLellis RA. Calcitonin immunoreactivity in neoplastic and hyperplastic parathyroid glands: an immunohistochemical study. Endocr Pathol. 2003; 14:249–255.CrossRefPubMed
8.
Schmid KW, Morgan JM, Baumert M, Fischer-Colbrie R, Böcker W, Jasani B. Calcitonin and calcitonin gene-related peptide mRNA detection in a population of hyperplastic parathyroid cells also expressing chromogranin B. Lab Investig J Tech Methods Pathol. 1995; 73:90–95.
9.
Juhlin CC, Haglund F, Obara T, Arnold A, Larsson C, Höög A. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours. Virchows Arch. 2011; 459:47–53.CrossRefPubMed
Metadata
Title
Diagnostic Pitfall: Parathyroid Carcinoma Expands the Spectrum of Calcitonin and Calcitonin Gene-Related Peptide Expressing Neuroendocrine Neoplasms
Authors
Anjelica Hodgson
Sara Pakbaz
Farnoosh Tayyari
James Edward Massey Young
Ozgur Mete
Publication date
01-06-2019
Publisher
Springer US
Published in
Endocrine Pathology / Issue 2/2019
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-019-9572-9

Other articles of this Issue 2/2019

Endocrine Pathology 2/2019 Go to the issue

OriginalPaper

Parathyroid Neoplasms: Immunohistochemical Characterization and Long Noncoding RNA (lncRNA) Expression

OriginalPaper

Negative Results on Thyroid Molecular Testing Decrease Rates of Surgery for Indeterminate Thyroid Nodules

OriginalPaper

Modified Transverse-Vertical Gross Examination: a Better Method for the Detection of Definite Capsular Invasion in Encapsulated Follicular-Patterned Thyroid Neoplasms

OriginalPaper

A Previously Unrecognized Monocytic Component of Pheochromocytoma and Paraganglioma

OriginalPaper

Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Update and Diagnostic Considerations—a Review

OriginalPaper

Revisiting the Significance of Prominent C Cells in the Thyroid
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits